1-甲烷磺酰基-4-苯氧基苯 | 21134-15-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-甲烷磺酰基-4-苯氧基苯
• 英文名称: 1-(4-(methylsulfonyl)phenoxy]benzene
• 英文别名: 1-(methylsulfonyl)-4-phenoxybenzene；4-phenoxyphenyl methyl sulfone；4-methylsulfonyl-diphenyl ether；4-Methylsulfonyl-diphenylaether；4-Methylsulfon-diphenylether；p-Phenoxyphenylmethylsulfon；1-Methanesulfonyl-4-phenoxybenzene；1-methylsulfonyl-4-phenoxybenzene
• CAS: 21134-15-6
• 化学式: C₁₃H₁₂O₃S
• 分子量: 248.302
• InChiKey: XVEKOLSQMFRDKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2909309090

反应信息

• 作为反应物：
  描述：

  1-甲烷磺酰基-4-苯氧基苯 在 palladium dihydroxide 氢气 、 sodium hydride 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.17h， 生成
  参考文献：
  名称：

  Synthesis of α-trifluoromethyl-α-amino-β-sulfone hydroxamates: novel nanomolar inhibitors of matrix metalloproteinases

  摘要：

  The racemic alpha-trifluoromethyl-alpha-amino-beta-sulfone hydroxamates 1 were synthesized by means of a nucleophilic addition of sulfur-stabilized carbanions to a N-Cbz imine of trifluoropyruvate (4). The free amino derivative 1a was the most potent inhibitor of both MMP-3 (stromelysin-1) and MMP-9 (gelatinase-B), showing an IC50 = 14 nM and 1 nM, respectively, and excellent selectivity versus MMP- 1 (>5000-fold difference in inhibitory capacity). The N-Me derivative 1b was the most selective for MMP-3 with respect to MMP-9 (62-fold difference). (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2005.07.078
• 作为产物：
  描述：

  4-苯氧基硫代苯酚 在 sodium hydroxide 、 双氧水 、 溶剂黄146 作用下， 生成 1-甲烷磺酰基-4-苯氧基苯
  参考文献：
  名称：

  Arcoria,A. et al., Gazzetta Chimica Italiana, 1961, vol. 91, p. 223 - 241

  摘要：

  DOI：

文献信息

• Sulfur-substituted diphenyl ethers having antiviral activity
  申请人：The Dow Chemical Company

  公开号：US04349568A1

  公开（公告）日：1982-09-14

  Novel compounds exhibiting antiviral activity are disclosed, such compounds are represented by the formula: ##STR1## wherein m represents the integer 0, 1 or 2; R represents trihalomethyl, alkyl or phenyl; R.sub.1 represents hydrogen, bromo, chloro, fluoro, cyano, nitro, amino, alkyl, alkoxy or trifluoromethyl; R.sub.2 represents hydroxyl, bromo, chloro, fluoro, cyano, acetyl, benzoyl, substituted benzoyl, alkyl, alkoxy, substituted alkoxy, benzyl, substituted benzyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, or the radical --O(CH.sub.2).sub.n R.sub.4 wherein n represents the integer 1, 2 or 3 and R.sub.4 represents cyano or dialkylamino; R.sub.3 represents hydrogen, hydroxyl, bromo, chloro, fluoro, cyano, acetyl, benzoyl, substituted benzoyl, alkyl, alkoxy, substituted alkoxy, benzyl, substituted benzyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, or the radical --O(CH.sub.2).sub.n R.sub.4 wherein n represents the integer 1, 2 or 3; and R.sub.4 represents cyano or dialkylamino; or alternatively R.sub.2 and R.sub.3 taken together represent the radical --O--C(X).sub.2 --O-- wherein X represents hydrogen, bromo, chloro or fluoro. Methods of using the above-noted compounds and structurally related compounds to employ their antiviral activity are also disclosed as well as pharmaceutically-acceptable compositions.

  披露了具有抗病毒活性的新型化合物，这些化合物可以用以下公式表示：##STR1## 其中，m代表整数0、1或2；R代表三卤甲基、烷基或苯基；R.sub.1代表氢、溴、氯、氟、氰、硝基、氨基、烷基、烷氧基或三氟甲基；R.sub.2代表羟基、溴、氯、氟、氰、乙酰基、苯甲酰基、取代的苯甲酰基、烷基、烷氧基、取代的烷氧基、苄基、取代的苄基、烷基亚砜、烷基亚磺酰基、烷基亚磺酰基、烷基氨磺酰基、二烷基氨磺酰基，或者自由基--O(CH.sub.2).sub.n R.sub.4，其中n代表整数1、2或3，R.sub.4代表氰或二烷基氨基；R.sub.3代表氢、羟基、溴、氯、氟、氰、乙酰基、苯甲酰基、取代的苯甲酰基、烷基、烷氧基、取代的烷氧基、苄基、取代的苄基、烷基亚砜、烷基亚磺酰基、烷基亚磺酰基、烷基氨磺酰基、二烷基氨磺酰基，或者自由基--O(CH.sub.2).sub.n R.sub.4，其中n代表整数1、2或3；R.sub.4代表氰或二烷基氨基；或者R.sub.2和R.sub.3共同代表自由基--O--C(X).sub.2 --O--，其中X代表氢、溴、氯或氟。还披露了使用上述化合物的结构相关化合物来发挥它们的抗病毒活性的方法，以及药物可接受的组合物。
• [EN] SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF<br/>[FR] ANTAGONISTES À PETITES MOLÉCULES DE LA MODIFICATION LIÉE AU SUMO DE CRMP2 ET LEURS UTILISATIONS
  申请人：UNIV ARIZONA

  公开号：WO2018144900A1

  公开（公告）日：2018-08-09

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperidinyl-benzoimidazole structure which function as antagonists of small ubiquitin like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2), and their use as therapeutics for the treatment of voltage gated sodium channel 1.7 (Nav1.7) related itch, anosmia, migraine event, and/or pain (e.g., neuropathic pain).

  这项发明属于药物化学领域。具体来说，该发明涉及一类具有哌啶基苯并咪唑结构的小分子，其作为小泛素样修饰物（SUMO）相关修饰（SUMOylation）的抗体，用作治疗与电压门控钠通道1.7（Nav1.7）相关的瘙痒、嗅觉丧失、偏头痛事件和/或疼痛（例如，神经病性疼痛）的治疗药物。
• Reverse hydroxamate inhibitors of matrix metalloproteinases
  申请人：Abbott Laboratories

  公开号：US06235786B1

  公开（公告）日：2001-05-22

  Compounds having the formula are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

  具有该公式的化合物是基质金属蛋白酶抑制剂。还公开了基质金属蛋白酶抑制组合物和在哺乳动物中抑制基质金属蛋白酶的方法。
• A General and Efficient Protocol for the Synthesis of Biaryl Ethers from Aryl Silyl Ethers Using Cs₂CO₃
  作者：Yan-Guang Wang、Sun-Liang Cui、Zhi-Yong Jiang

  DOI：10.1055/s-2004-829567

  日期：——

  Biary ethers are known to be important organic compounds for their biological interests and great presence in life science industries. A number of them have consequently provide a strong incentive for synthesis, which includes the classical Ullman reaction, metal-catalyzed substitution, SN-Ar based type, intramolecular oxidative coupling and MW-assisted methods. Although the above synthetic strategies

  众所周知，二元醚是重要的有机化合物，因为它们具有生物学意义，并且在生命科学行业中占有重要地位。因此，它们中的一些为合成提供了强大的动力，包括经典的 Ullman 反应、金属催化取代、基于 SN-Ar 的类型、分子内氧化偶联和 MW 辅助方法。虽然上述合成策略特别重要，但需要一种方法将苯氧基硅烷直接转化为联芳醚，而无需求助于水解条件。……
• BINDING INHIBITORS OF THE BETA. TRANSDUCIN REPEAT-CONTAINING PROTEIN
  申请人：Bradley Mark

  公开号：US20190106460A1

  公开（公告）日：2019-04-11

  The present invention relates to compounds which bind to Beta Trans-ducin repeat-containing protein (βTrCP), and modulate the activity of βTrCP. In particular, the invention relates to compounds which demonstrate optimised binding to PTrCP. The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds as medicaments, specifically for the treatment of disorders associated with aberrant protein degradation, such as cancer. The preferred binding inhibitors are peptides derived from the motive DSGXXS, e.g. DEGFWE, DDGFWD and Succinyl-EGFWE.

  本发明涉及与Beta Trans-ducin重复含蛋白（βTrCP）结合并调节βTrCP活性的化合物。特别是，本发明涉及表现出对PTrCP优化结合的化合物。本发明还涉及包含这种化合物的制药组合物以及将这种化合物用作药物的用途，特别是用于治疗与异常蛋白降解相关的疾病，如癌症。首选的结合抑制剂是从DSGXXS动机中派生的肽，例如DEGFWE，DDGFWD和Succinyl-EGFWE。